United States Squamous-Cell Carcinoma of the Larynx Epidemiology Report 2022-2042
May 26, 2023 07:08 ET
|
Research and Markets
Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "Squamous-Cell Carcinoma of the Larynx in the United States, 2022-2042: Cancer Populations USA Report and Data Dashboard" report has been added to ...
United States Squamous-Cell Carcinoma of the Oral Cavity Epidemiology Report 2022-2042
May 25, 2023 10:38 ET
|
Research and Markets
Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Squamous-Cell Carcinoma of the Oral Cavity in the United States, 2022-2042: Cancer Populations USA Report and Data Dashboard" report has been added to ...
United States Larynx Cancer Epidemiology Report 2022-2042
May 25, 2023 10:33 ET
|
Research and Markets
Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Larynx Cancer in the United States, 2022-2042: Cancer Populations USA Report and Data Dashboard" report has been added to ResearchAndMarkets.com's...
United States Non-Small-Cell Lung (NSCL) Cancer Epidemiology Report 2022-2042
May 25, 2023 10:13 ET
|
Research and Markets
Dublin, May 25, 2023 (GLOBE NEWSWIRE) -- The "Non-Small-Cell Lung Cancer in the United States, 2022-2042: Cancer Populations USA Report and Data Dashboard" report has been added to ...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
May 24, 2023 08:40 ET
|
Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
Posting of Annual Report & Notice of AGM
May 22, 2023 16:15 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
May 18, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
2023 Bispecific CD3 Molecules in Oncology Analytical Tool: Covering 67 Companies Plus Partners who are Today Developing 148 Bispecific CD3 Drugs
May 16, 2023 12:18 ET
|
Research and Markets
Dublin, May 16, 2023 (GLOBE NEWSWIRE) -- The "Bispecific CD3 Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.There is a considerable and robust...
Ocean Biomedical (NASDAQ: OCEA) Announces 70% Increase in Price Target by EF Hutton from $10 to $17 on New Glioblastoma Results Validating Profound Tumor Suppression with Anti-Chi3L1 Antibody
May 01, 2023 08:01 ET
|
Ocean Biomedical, Inc.
Providence, RI, May 01, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling...
Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report 2023: A $2.3 Billion Market by 2030 - High Demand for Advanced Medicines and Implementation of International Standards by CROs
February 24, 2023 06:43 ET
|
Research and Markets
Dublin, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The "Oncology Based In-vivo CRO Market Size, Share & Trends Analysis Report By Indication (Blood Cancer, Solid Tumor), By Region, And Segment Forecasts,...